Literature DB >> 8363727

Myasthenia gravis: recognition of a human autoantigen at the molecular level.

M P Protti1, A A Manfredi, R M Horton, M Bellone, B M Conti-Tronconi.   

Abstract

The symptoms of myasthenia gravis are primarily or exclusively due to an autoimmune response against the muscle nicotinic acetylcholine receptor (AChR) and this has been the object of intensive investigations for almost 20 years. A detailed picture at the molecular level of the interaction of this autoantigen with the key elements involved in the autoimmune response, such as anti-AChR antibodies, the T-cell receptor and restricting major histocompatibility complex molecules, is now emerging for both human myasthenia gravis and its experimental model, experimental autoimmune myasthenia gravis. Here, Maria Pia Protti and colleagues focus on the molecular interactions occurring in human myasthenia gravis and summarize recent information on pathogenic mechanisms of the autoimmune response, and the structure of epitopes recognized by B cells and CD4+ T cells of myasthenic patients on the AChR molecule.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363727     DOI: 10.1016/0167-5699(93)90237-F

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  11 in total

1.  Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.

Authors:  Jie Luo; Alexander Kuryatov; Jon M Lindstrom
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

2.  Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.

Authors:  F Baggi; F Andreetta; E Caspani; M Milani; R Longhi; R Mantegazza; F Cornelio; C Antozzi
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

3.  Galectin-1 is expressed by thymic epithelial cells in myasthenia gravis.

Authors:  C Hafer-Macko; M Pang; J J Seilhamer; L G Baum
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

4.  Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit.

Authors:  D Barchan; M C Souroujon; S H Im; C Antozzi; S Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Presentation of endogenous acetylcholine receptor antigen to a specific CD4+ T-cell line by a transfected B-cell line.

Authors:  A F Mulcahy; D M Beeson; N Willcox; A G Diamond
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

6.  Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains.

Authors:  Jon Lindstrom; Jie Luo; Alexander Kuryatov
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

7.  Involvement of human muscle acetylcholine receptor alpha-subunit gene (CHRNA) in susceptibility to myasthenia gravis.

Authors:  H J Garchon; F Djabiri; J P Viard; P Gajdos; J F Bach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

8.  Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects.

Authors:  L Moiola; P Karachunski; M P Protti; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

9.  Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases.

Authors:  K W Wucherpfennig; J L Strominger
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

10.  HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases.

Authors:  S Shimoda; M Nakamura; H Ishibashi; K Hayashida; Y Niho
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.